The "new" bronchopulmonary dysplasia: Part I [La "nueva" displasia broncopulmonar. Parte I]
Por:
Lule Morales M.S., Guzmán Grenfell A.M., Sierra Vargas M.P., Torres Ramos J.D.
Publicada:
1 ene 2008
Categoría:
Pulmonary and Respiratory Medicine
Resumen:
In 1967, Northway et ál, published the "classical" description of the bronchopulmonary dysplasia (BPD). Changes occurred to this entity in the last four decades motivated the National Heart, Lung, and Blood Institute to define updated criteria of the "new" BPD. Emphasis was put in prematurely born before 32 gestational weeks, since normal alveolar and vascular development is interrupted, and in the early therapeutic use of supplementary oxygen, which joined to the metabolic immaturity, favors the production of reactive oxygen species that provoke pulmonary damage in the "new" BPD. Owing to continuing advances in technology and research, survival of extremely premature babies (< 1,000 g) is increasing, which leads to a higher number of children with chronic sequelae of BPD. Therefore, the objective of the present work was to present a review of the current knowledge of physiopathogenic and therapeutic changes occurred in this disease.
Filiaciones:
Lule Morales M.S.:
UNAM, Médico Adscrito del Servicio Neumología Pediátrica, Ismael Cosío Villegas (INER), Mexico
Guzmán Grenfell A.M.:
Laboratorio de Química Inorgánica, Unidad de Investigación, INER, Mexico
Sierra Vargas M.P.:
Laboratorio de Química Inorgánica, Unidad de Investigación, INER, Mexico
Torres Ramos J.D.:
Laboratorio de Química Inorgánica, Unidad de Investigación, INER, Mexico
|